AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akada, J. K.
Right arrow Articles by Nakazawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akada, J. K.
Right arrow Articles by Nakazawa, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1999, p. 1072-1076, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Anti-Helicobacter pylori Activities of New Rifamycin Derivatives, KRM-1648 and KRM-1657

Junko K. Akada,1 Mutsunori Shirai,1 Kenji Fujii,2 Kiwamu Okita,3 and Teruko Nakazawa1,*

Department of Microbiology1 and First Department of Internal Medicine,3 Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, and KANEKA Corporation, Takasago Research Laboratories, Takasago, Hyogo 676-8688,2 Japan

Received 27 July 1998/Returned for modification 5 November 1998/Accepted 27 February 1999

The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated for their in vitro antimicrobial activities against 44 strains of Helicobacter pylori. Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of isolates are inhibited for these drugs were lower (0.002 and 0.008 µg/ml, respectively) than those of amoxicillin and rifampin for H. pylori. Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be useful for the eradication of H. pylori infections.

* Corresponding author. Mailing address: Department of Microbiology, Yamaguchi University School of Medicine, 1144, kogushi, Ube, Yamaguchi 755-8505, Japan. Phone: 81-836-22-2226. Fax: 81-836-22-2227. E-mail: nakazawa{at}po.cc.yamaguchi-u.ac.jp.

Antimicrobial Agents and Chemotherapy, May 1999, p. 1072-1076, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.